AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00392379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lozenge
Description: Placebo lozenge
Study NCT04271644 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA CAR-T cells
Description: BCMA CAR-T cell therapy
Study NCT05304780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: needs-tailored nurse-led recovery program
Description: The needs-tailored nurse-led recovery program were divided into five major stages of care, which were build partnership, conduct integrated needs assessment, set needs-based recovery goals and provide empowerment-oriented care, conduct continuous monitoring of goals, and conduct effectiveness evaluations.
Study NCT03443986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training associated with vibration
Description: The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration and 5 minutes of slowdown.
Study NCT02029378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Study NCT01123993 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Music CD
Description: During 4-week interventional period of each group, a researcher gives a CD to care giver and advises him/her to open the music for patient for at least 60 minutes daily, after dinner to bedtime. Meanwhile, the care giver notes the exact duration that patient actually listens to it in the calendar provided and returns the CD and document to the researcher at the end of interventional period.
Study NCT04375319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT
Description: OCT can provide clear in vivo imaging and evaluate the vascular repair after stent implantation by measuring the optical echo of near-infrared light reflection
Study NCT00361933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: valganciclovir open label, two 450mg tablets orally, twice a day
Study NCT03443986 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Resistance training associated with vibration sham
Description: he workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration sham and 5 minutes of slowdown.
Study NCT00709709 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multislice coronary scan
Description: multislice coronary scan
Study NCT03935113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: In KT group, KT was applied using the insertion-origin muscle and space-correction technique of affected upper limb with stroke patients.
Study NCT00067938 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lamotrigine
Description: Lamotrigine
Study NCT00392145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard IV rehydration
Description: A 20 mL/kg 0.9% normal saline bolus (maximum 999 mL) will be administered over 1 hour. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
Study NCT01524718 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Imaging with two X-ray image intensifiers
Description: Two fluoroscopy apparatus one in the AP plane and the other as the axial plane.
Study NCT02755714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide spray
Description: The patient will - or will not - receive Ipratropium bromide spray (MDI) 20 μg given through a plastic spacer two puffs 1 hour before a continuous laryngoscopy exercise test (CLE-test)
Study NCT02247752 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: inactive carrier
Description: Yearly demographic, clinic, biologic and ultrasonic data collection realized during usual follow-up as recommended.~Yearly centralisation of a complementary biological analysis in Paul Brousse Hospital laboratory of virology.
Study NCT03904303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A 06 ad
Description: Colonic cleansing before colonoscopy and CT colonografi
Study NCT03904303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A 06 ad
Description: Colonic cleansing before colonoscopy and CT colonografi
Study NCT03992586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearing pink glasses
Description: Wearing pink-colored lenses
Study NCT03992586 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wearing clear glasses
Description: Wearing clear glasses
Study NCT02475954 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TH-CBT
Description: The TH-CBT group will receive the study intervention and standard care. The study treatment has been previously manualized and modified for remote administration, as described in the introduction to the revised application.12 PD Veterans will receive 10 weekly individual sessions (60 minutes each) of CBT, delivered via Video-to-Home (V2H).
Study NCT02475954 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard Care is defined as medical and psychiatric treatment provided by patients' personal doctors (e.g., neurologists, psychiatrists, therapists). Veterans will continue to receive routine clinical care and will remain on all depression treatments that they were receiving prior to their study (e.g., stable anti-depressant medications, established psychotherapy, clinical monitoring).
Study NCT02475954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard Care is defined as medical and psychiatric treatment provided by patients' personal doctors (e.g., neurologists, psychiatrists, therapists). Veterans will continue to receive routine clinical care and will remain on all depression treatments that they were receiving prior to their study (e.g., stable anti-depressant medications, established psychotherapy, clinical monitoring).
Study NCT00392145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid intravenous rehydration (RIVR)
Description: A 60 mL/kg 0.9% normal saline bolus (maximum 999 mL) over 1 hour will be administered. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
Study NCT01607827 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polyp removal upon insertion and withdrawal
Description: Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist removed all visible polyps instantly regardless whether advancing the instrument to the cecum or pulling back.
Study NCT01607827 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Polyp removal upon withdrawal only
Description: Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist advanced the endoscope to the cecum without removing polyps. Upon withdrawal, all visible polyps were removed successively by standard techniques.
Study NCT01227967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine, Ribavirin, Oseltamivir
Description: Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg, three capsules of Ribavirin 200 mg for total of 600 mg, and one capsule of Amantadine 100 mg.
Study NCT00301366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-1 proteinase inhibitor (human)
Description: 60 mg/kg weekly for 20 weeks
Study NCT00537225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: tailored multifactor CVD risk reduction
Study NCT02630043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: Tolcapone is an oral agent that will be administered every day of each 21-day cycle during Cycle 1 and in combination with oxaliplatin during cycles 2-5 given IV on Day 1 of each 21-day cycle.
Study NCT02630043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be given starting in Cycle 2 at 100 mg/m2 IV on Day 1 of each 21-day cycle
Study NCT01227967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
Study NCT04604132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib
Description: Derazantinib was administered orally at a dose of 300 mg once daily as monotherapy in the Substudy 1 (Cohort 1.1).
Study NCT04604132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib-paclitaxel-ramucirumab combination
Description: Derazantinib was administered orally at a dose of 200 mg once daily in combination with paclitaxel and ramucirumab.~Paclitaxel was administered intravenously at a dose of 80 mg/m² on days 1, 8, and 15 of a 28-day cycle in combination with ramucirumab.~Ramucirumab was administered intravenously at a dose of 8 mg/kg every 2 weeks in combination with paclitaxel.
Study NCT04604132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib-paclitaxel-ramucirumab combination
Description: Derazantinib was administered orally at a dose of 300 mg once daily in combination with paclitaxel and ramucirumab.~Paclitaxel was administered intravenously at a dose of 80 mg/m² on days 1, 8, and 15 of a 28-day cycle in combination with ramucirumab.~Ramucirumab was administered intravenously at a dose of 8 mg/kg every 2 weeks in combination with paclitaxel.
Study NCT04604132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib
Description: Derazantinib was administered orally at a dose of 200 mg twice daily as monotherapy in the Substudy 1 (Cohort 1.3).
Study NCT04604132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib
Description: Derazantinib was administered orally at a dose of 300 mg once daily as monotherapy in the Substudy 1 (Cohort 1.2).
Study NCT00952380 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dalteparin
Description: dalteparin subcutaneous injection
Study NCT04821505 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: didactic classroom instruction on improving ones lifestyle through healthier diet, exercise and control of substance use.
Study NCT04821505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Description: TM is described as simple technique practiced 20 minutes twice a day for deep rest and relaxation.
Study NCT02206178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine combination with acetaminophen
Study NCT02206178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetylcysteine combination with acetaminophen
Study NCT02627040 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InterTan Intertrochanteric Nail
Description: Cephalomedullary fixation of intertrochanteric fracture with an InterTan Intertrochanteric Nail
Study NCT02627040 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gamma 3 Intertrochanteric Nail
Description: Cephalomedullary fixation of intertrochanteric fracture with an Gamma 3 Intertrochanteric Nail
Study NCT02206178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03364829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol/Glycopyrronium
Study NCT03131830 — intervention group
Intervention type: OTHER
Intervention: Online-based questionnaire
Description: Participants receive a web-link to a questionnaire, which is active for 3 months
Study NCT02521896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Steerable Sheath System
Description: The Vado™ Steerable Sheath consists of a dilator and steerable sheath which are designed to provide intracardiac access and flexible catheter positioning in the cardiac anatomy.
Study NCT01532141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 50 mg BIA 9-1067 (single-dose)
Study NCT00183729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day.
Study NCT01532141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: 1 mg rasagiline (single-dose)
Study NCT01231412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSCT
Study NCT00183729 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo distribution is planned to mimic the active drug.
Study NCT04479319 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thorax CT
Description: Subjects in all arms have a Thorax CT and RT-PCR for SARS-CoV-2.
Study NCT03199755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACT
Description: Current approved drug for treating malaria
Study NCT01231412 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSCT
Study NCT01231412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO or IV
Study NCT01231412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Given PO or IV
Study NCT03199755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLA1
Description: Experimental drug treatment, single dose.
Study NCT03199755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLA2
Description: Experimental drug treatment, doubled the dose of DLA1.
Study NCT01231412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01231412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01231412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT01231412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT01231412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSCT
Study NCT01231412 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSCT
Study NCT01231412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT01231412 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT01231412 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT02316834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02316834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 673
Description: BMN673 given at a dose of 1 mg orally once daily.~Participants begin taking BMN 673 tablets by mouth every day, starting on the day of scheduled laparoscopy. Participants take the study drug for at least 7 days before scheduled tumor reduction surgery.
Study NCT02924701 — intervention group
Intervention type: OTHER
Intervention: Blood samples, fibroscan and questionaires
Study NCT01201213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Single bolus of drug for pain relief in early labour
Study NCT00166387 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: A single blood draw.
Study NCT00032084 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation intervention
Description: Physician will deliver the smoking cessation advice, reinforce the established quit date (no sooner than seven days after starting bupropion/placebo), and will distribute patient educational materials and all pharmacotherapy
Study NCT00032084 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: smoking cessation intervention
Description: Physician will deliver the smoking cessation advice, reinforce the established quit date (no sooner than seven days after starting bupropion/placebo), and will distribute patient educational materials and all pharmacotherapy
Study NCT00032084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion hydrochloride
Description: 150 mg/day on Days 1-3, 300 mg/day on Day 4-77
Study NCT00032084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine
Description: 21 mg patch/day for Weeks 2-7; 14 mg patch/day for Weeks 8-9; 7 mg patch/day for Weeks 10-11.
Study NCT00032084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nicotine
Description: 21 mg patch/day for Weeks 2-7; 14 mg patch/day for Weeks 8-9; 7 mg patch/day for Weeks 10-11.
Study NCT00032084 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care
Description: The nurse/CRA will debrief the patients after the brief physician intervention and will follow-up with a series of 5 phone calls to provide booster advice. All advice will be based on the stage of change model (i.e., tailored to the patient's readiness to quit and/or stay off cigarettes).
Study NCT00032084 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: psychosocial assessment and care
Description: The nurse/CRA will debrief the patients after the brief physician intervention and will follow-up with a series of 5 phone calls to provide booster advice. All advice will be based on the stage of change model (i.e., tailored to the patient's readiness to quit and/or stay off cigarettes).
Study NCT01384292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 12.5 mg oral tablet once daily
Study NCT01384292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 25 mg oral tablet once daily
Study NCT01384292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral treatment
Study NCT03119012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg/day
Study NCT03119012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: 120mg/day
Study NCT03119012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 100mg/day
Study NCT01750255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmaceutical Care
Description: Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy; Depression and Mania Rating Scale, Clinical Global Assessment Scale, Quality of life and adherence to treatment
Study NCT01750255 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life (Sf - 36 test), adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.
Study NCT03065829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASSIST
Description: Wearable sensor technology delivering mindfulness meditation training (MMT) and health promotion (sleep hygiene and physical activity) .
Study NCT03065829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention-Control
Description: Wearable sensor technology only viewing biophysical sensor data.
Study NCT01133964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dairy proteins
Description: Protein drinks with 3.5% protein. The protein source will be whey, casein or whey and casein (20:80; normal content in the milk). In the arm with water no protein will be added.
Study NCT01133964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: dairy proteins
Description: Protein drinks with 3.5% protein. The protein source will be whey, casein or whey and casein (20:80; normal content in the milk). In the arm with water no protein will be added.